14-ICML - 14th INTERNATIONAL CONFERENCE ON MALIGNANT LYMPHOMA Lugano, Switzerland – June 14-17, 2017 www.lymphcon.ch SCIENTIFIC PROGRAM (as of June 05, 2017) ______________________________________________________________________________________

Tuesday, June 13, 2017

08:00 – 17:30 Auditorium (Lugano University)

CLOSED WORKSHOP - DESIGN OF CLINICAL TRIALS: BIOLOGICAL AND CLINICAL ENDPOINTS IN THE DESIGN OF FUTURE CLINICAL TRIALS Co-chairs: A. Younes, New York, NY (USA) and E. Zucca, Bellinzona (Switzerland) Organized in co-operation with American Association for Cancer Research – AACR and European School of Oncology – ESO by invitation only

15:00 – 17:30 Aula Magna (Lugano University)

WORKSHOP - NOVEL ISSUES IN THE COMBINED MODALITY TREATMENT OF LYMPHOMAS Co-chairs: M.K. Gospodarowicz, Toronto (Canada) and L. Specht, Copenhagen (Denmark) Organized by International Lymphoma Radiation Oncology Group - ILROG open to all 14-ICML attendees

PART 1: IMMUNOMODULATORY TREATMENT IN THE COMBINED MODALITY SETTING 15:00 IMMUNOMODULATORY TREATMENT AND RADIATION THERAPY IN LYMPHOMAS

T.M. Illidge, Manchester (UK) 15:15 IMMUNOMODULATORY TREATMENT, ALONE OR IN COMBINATION WITH OTHER

TREATMENT MODALITIES IN THE TREATMENT OF LYMPHOMAS C. Moskowitz, New York, NY (USA)

15:30 GENERATING AN ABSCOPAL EFFECT BY RADIOTHERAPY FOLLOWED BY

CHECKPOINT INHIBITORS IN INDOLENT LYMPHOMAS M.L. Palomba, New York, NY (USA)

15:45 PANEL DISCUSSION

T.M. Illidge, Manchester (UK), C. Moskowitz, New York, NY (USA), M.L. Palomba, New York, NY (USA), M.K. Gospodarowicz, Toronto (Canada) and L. Specht, Copenhagen (Denmark)

16:00 - 16:30 COFFEE BREAK - inside Aula Magna (Lugano University) for workshop attendees PART 2: NK/T-CELL LYMPHOMAS, AN EMERGING LYMPHOMA TYPE WITH SPECIAL

ISSUES 16:30 NK/T-CELL LYMPHOMAS IN ASIA. TREATMENT PRINCIPLES. WHAT RADIATION

THERAPY? WHAT CHEMOTHERAPY REGIMEN? WHEN TO COMBINE AND WHEN TO USE SINGLE MODALITY? M. Oguchi, Tokyo (Japan)

16:45 NK/T-CELL LYMPHOMAS IN THE WESTERN WORLD. EXPERIENCE WITH COMBINED

MODALITY TREATMENT AT MSKCC S.M. Horwitz, New York, NY (USA)

17:00 THE BEIJING EXPERIENCE WITH RADIATION ALONE

Y.-X. Li, Beijing (China) 17:15 PANEL DISCUSSION

M. Oguchi, Tokyo (Japan), S.M. Horwitz, New York, NY (USA), Y.-X. Li, Beijing (China), L. Specht, Copenhagen (Denmark) and M.K. Gospodarowicz, Toronto (Canada)

_______________________________________________________________________________________ Wednesday, June 14, 2017

08:30 – 12:00 POSTER SESSION SET UP Marquee

08:30 – 09:15

“MEET THE PROFESSOR” SESSIONS · 5 parallel sessions

Room A

CHEMOTHERAPY-FREE TREATMENT OF INDOLENT LYMPHOMAS J.W. Friedberg, Rochester, NY (USA) repeated on Thursday, June 15, in Aula Magna (Lugano University)

Room B and Marquee

THE 2016 UPDATED WHO CLASSIFICATION OF LYMPHOID NEOPLASIAS L. Quintanilla-Martinez, Tuebingen (Germany) repeated on Friday, June 16 in Cinema Corso

Cinema Corso ROLE AND TIMING OF NEW DRUGS IN CLL

M. Hallek, Cologne (Germany) repeated on Friday, June 16, in Room A

Auditorium (Lugano University)

THE ROLE OF STEM CELL TRANSPLANT FOR LYMPHOMA IN 2017 J.G. Gribben, London (UK) repeated today at 09:30 in Auditorium (Lugano University)

Aula Magna (Lugano University)

THE COSTS OF CARE IN HAEMATOLOGICAL CANCERS: HEALTH ECONOMIC ISSUES M.F. Fey, Bern (Switzerland) offered only once

09:30 – 10:15

5 parallel sessions

Room A

RESPONSE-ADAPTED THERAPY IN HODGKIN LYMPHOMA P.W.M. Johnson, Southampton (UK) repeated on Thursday, June 15, in Cinema Corso

Room B and Marquee

DISEASE-ORIENTED TREATMENT OF T-CELL LYMPHOMAS K. Tobinai, Tokyo (Japan) offered only once

Cinema Corso CLINICAL APPLICATIONS OF GENOME STUDIES

A. Younes, New York, NY (USA) repeated on Thursday, June 15, in Room B

Auditorium (Lugano University)

THE ROLE OF STEM CELL TRANSPLANT FOR LYMPHOMA IN 2017 J.G. Gribben, London (UK)

Aula Magna (Lugano University)

THE MULTIPLE FACETS OF MARGINAL ZONE LYMPHOMAS M. Raderer, Vienna (Austria) repeated on Friday, June 16, in Room B

10:15 – 10:35

COFFEE BREAK

Marquee

10:35 – 12:00

EDUCATIONAL SYMPOSIA · 2 parallel sessions

Room A, Cinema Corso and Aula Magna (Lugano University)

AGGRESSIVE LYMPHOMAS Chair: E. Campo, Barcelona (Spain)

MOLECULAR GENETICS OF AGGRESSIVE B CELL LYMPHOMAS R. Dalla-Favera, New York, NY (USA)

PATHOLOGY AND CLASSIFICATION OF AGGRESSIVE MATURE B-CELL LYMPHOMAS E. Campo, Barcelona (Spain)

TREATMENT OF AGGRESSIVE B-CELL LYMPHOMAS S.M. Smith, Chicago, IL (USA)

Room B and Marquee

IMMUNOTHERAPY IN LYMPHOMAS Chair: S.M. Ansell, Rochester, MN (USA)

IMMUNOLOGY

F. Caligaris-Cappio, Milan (Italy) CAR T-CELLS

D.G. Maloney, Seattle, WA (USA) CHECKPOINT INHIBITORS

S.M. Ansell, Rochester, MN (USA)

12:00 – 18:30 Marquee

Abstract number

POSTER SESSION (printing and delivery of the posters sponsored by Takeda Oncology)

140 - 163 PATHOLOGY AND BIOLOGY 164 - 177 HODGKIN LYMPHOMA 178 - 204 AGGRESSIVE LYMPHOMAS 205 - 214 MANTLE CELL LYMPHOMA 215 - 234 INDOLENT LYMPHOMAS 235 - 241 CLL 242 - 257 NK and T-CELL LYMPHOMAS 258 - 289 NEW DRUG DEVELOPMENT

12:00 – 13:00 Marquee

LUNCH TIME AND POSTER VIEWING

13:00 – 14:00 Room A, B, Marquee, Cinema Corso and Aula Magna (Lugano University)

OPENING OF THE CONFERENCE · WELCOME AND INTRODUCTORY REMARKS F. Cavalli, Bellinzona (Switzerland)

HENRY KAPLAN MEMORIAL LECTURE AND ICML PRIZE· Laudatio: A. Lanzavecchia, Bellinzona (Switzerland) 001 IMMUNOTHERAPY COMES OF AGE TO TREAT LYMPHOMAS

R. Levy, Stanford, CA (USA)

14:00 – 15:15 Room A, B, Marquee, Cinema Corso and Aula Magna (Lugano University)

PLENARY SESSION Co-chairs: J.M. Vose, Omaha, NE (USA) and J.W. Friedberg, Rochester, NY (USA)

14:00 004 INTERIM REPORT FROM A PHASE 2 MULTICENTER STUDY OF TAZEMETOSTAT,

AN EZH2 INHIBITOR, IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMAS

F. Morschhauser, Lille (France) 14:15 Discussant: T.E. Witzig, Rochester, MN (USA) 14:25 005 CRISPR-Cas9 GENETIC SCREENS UNCOVER A B CELL RECEPTOR-MYD88

SUPERPATHWAY IN DIFFUSE LARGE B CELL LYMPHOMA R.M. Young, Bethesda, MD (USA) 14:40 Discussant: R. Dalla-Favera, New York, NY (USA) 14:50 006 BENDAMUSTINE (B), FOLLOWED BY OBINUTUZUMAB (G) AND VENETOCLAX (A)

IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): CLL2-BAG TRIAL OF THE GERMAN CLL STUDY GROUP (GCLLSG)

P. Cramer, Cologne (Germany) Best Abstract Merit Award, sponsored by Swiss Cancer League Foundation

15:05 Discussant: D. Rossi, Bellinzona (Switzerland) 15:15 – 15:40 Marquee, Cinema Corso and Aula Magna (Lugano University)

COFFEE BREAK

15:40 – 16:40 Room A, B, Marquee, Cinema Corso and Aula Magna (Lugano University)

AACR-ICML JOINT SESSION - CANCER IMMUNOTHERAPY Co-chairs: F. Cavalli, Bellinzona (Switzerland) and M. Foti, Philadelphia, PA (USA)

15:40 007 GLOBAL PIVOTAL PHASE 2 TRIAL OF THE CD19-TARGETED THERAPY CTL019 IN

ADULT PATIENTS WITH RELAPSED OR REFRACTORY (R/R) DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)—AN INTERIM ANALYSIS

S.J. Schuster, Philadelphia, PA (USA) 15:55 008 AXICABTAGENE CILOLEUCEL (AXI-CEL; KTE-C19) IN PATIENTS WITH

REFRACTORY AGGRESSIVE NON-HODGKIN LYMPHOMAS (NHL): PRIMARY RESULTS OF THE PIVOTAL TRIAL ZUMA-1

S.S. Neelapu, Houston, TX (USA) 16:10 009 WHAT CAN WE LEARN REGARDING IMMUNOTHERAPY FROM MALIGNANT

MELANOMA? A.M.M. Eggermont, Villejuif (France) 16:25 010 WHAT CAN WE LEARN REGARDING IMMUNOTHERAPY FROM LUNG CANCER? R. Stahel, Zurich (Switzerland) 16:40 – 17:00 BREAK

17:00 – 18:00

“FOCUS ON…” SESSIONS 5 parallel sessions

Room A CLASSICAL THERAPIES FOR FOLLICULAR LYMPHOMA Chair: A.T. Lister, London (UK) 17:00 011 OUTCOME OF CURATIVE RADIOTHERAPY FOR LOCALISED FOLLICULAR

LYMPHOMA IN THE ERA OF 18F-FDG PET-CT STAGING: AN INTERNATIONAL COLLABORATIVE STUDY ON BEHALF OF ILROG

J.L. Brady, London (UK) 17:10 012 CVP OR R-CVP GIVEN AFTER INVOLVED-FIELD RADIOTHERAPY IMPROVES

PROGRESSION FREE SURVIVAL IN STAGE I-II FOLLICULAR LYMPHOMA: RESULTS OF AN INTERNATIONAL RANDOMIZED TRIAL

M.P. MacManus, Melbourne (Australia) 17:20 013 RITUXIMAB MAINTENANCE VERSUS OBSERVATION AFTER

IMMUNOCHEMOTHERAPY (R-CHOP, R-MCP, R-FCM) IN PREVIOUSLY UNTREATED FOLLICULAR LYMPHOMA: A RANDOMISED TRIAL OF GLSG AND OSHO

E. Hoster, Munich (Germany) 17:30 014 DURABLE BENEFIT OF RITUXIMAB MAINTENANCE POST-AUTOGRAFT IN

PATIENTS WITH RELAPSED FOLLICULAR LYMPHOMA: 12-YEAR FOLLOW-UP OF THE EBMT LYMPHOMA WORKING PARTY LYM1 TRIAL

R. Pettengell, London (UK) 17:40 015 LONG TERM RESULTS OF THE FOLL05 RANDOMIZED STUDY COMPARING R-CVP

WITH R-CHOP AND R-FM AS FIRST LINE THERAPY IN PATIENTS WITH ADVANCED STAGE FOLLICULAR LYMPHOMA. A FIL STUDY

S. Luminari, Reggio Emilia (Italy) 17:50 016 CAUSE OF DEATH IN FOLLICULAR LYMPHOMA IN THE RITUXIMAB ERA: A

POOLED ANALYSIS OF FRENCH AND US COHORTS C. Sarkozy, Pierre Bénite (France) Room B and Marquee

PET/CT: VISUAL ASSESSMENT AND BEYOND Chair: B.D. Cheson, Washington D.C. (USA)

17:00 017 PROGNOSTIC VALUE OF BASELINE TOTAL METABOLIC TUMOR VOLUME (TMTV)

FOR PATIENTS WITH EARLY STAGE HODGKIN LYMPHOMA ENROLLED IN THE STANDARD ARM OF THE H10 (EORTC/LYSA/FIL) TRIAL

A. Cottereau, Paris (France) 17:10 018 BASELINE METABOLIC TUMOR VOLUME IS AN INDEPENDENT PROGNOSTIC

FACTOR FOR RELAPSED AND REFRACTORY HODGKIN LYMPHOMA PATIENTS RECEIVING PET-ADAPTED SALVAGE THERAPY WITH BRENTUXIMAB VEDOTIN AND AUGMENTED ICE

A.J. Moskowitz, New York, NY (USA) 17:20 019 CAN BASELINE PET-CT FEATURES PREDICT OUTCOMES IN ADVANCED

HODGKIN LYMPHOMA? A PROSPECTIVE EVALUATION OF UK PATIENTS IN THE RATHL TRIAL (CRUK/07/033)

L.C. Pike, London (UK) 17:30 020 CLINICAL CHARACTERISTICS OF PATIENTS WITH NEGATIVE INTERIM-PET AND

POSITIVE FINAL PET: DATA FROM THE PROSPECTIVE PET-ORIENTED HD0801 STUDY BY FONDAZIONE ITALIANA LINFOMI (FIL)

L. Rigacci, Florence (Italy)

17:40 021 PROGNOSTIC VALUE OF PET-CT AFTER FIRST-LINE IMMUNOCHEMOTHERAPY FOR FOLLICULAR LYMPHOMA IN THE PHASE III GALLIUM STUDY

J. Trotman, Sydney (Australia) 17:50 022 FDG-PET AS A BIOMARKER OF RESPONSE IN DLBCL: THE HOVON 84 STUDY

EXPERIENCE C.N. Burggraaff, Amsterdam (The Netherlands) Cinema Corso CLINICO-PATHOLOGICAL CORRELATIONS Chair: E.S. Jaffe, Bethesda, MD (USA) 17:00 023 NON-MEDIASTINAL CASES OF GREY ZONE LYMPHOMA: A PATHOLOGICAL AND

CLINICAL SERIES OF 17 CASES FROM THE LYSA C. Sarkozy, Pierre Bénite (France) 17:10 024 FOXP1 EXPRESSION IS INVERSELY CORRELATED WITH EZH2 MUTATION

STATUS AND PREDICTS POOR FAILURE-FREE SURVIVAL IN FOLLICULAR LYMPHOMA TREATED WITH RITUXIMAB AND CHEMOTHERAPY

A. Mottok, Vancouver (Canada) 17:20 025 ELEVATED EXPRESSION OF LAG3 IS ASSOCIATED WITH POOR OUTCOME IN

PATIENTS WITH DLBCL TREATED WITH R-CHOP C. Keane, Woolloongabba (Australia) 17:30 026 CELL OF ORIGIN COMBINED WITH CNS INTERNATIONAL PROGNOSTIC INDEX

IMPROVES IDENTIFICATION OF DLBCL PATIENTS WITH HIGH CNS RELAPSE RISK AFTER INITIAL IMMUNOCHEMOTHERAPY

M. Klanova, Prague (Czech Republic) 17:40 027 NKP46 EXPRESSION IS A DIAGNOSTIC AND PROGNOSTIC BIOMARKER IN

PRIMARY GASTROINTESTINAL T-CELL LYMPHOPROLIFERATIONS. A CELAC NETWORK STUDY

M. Cheminant, Paris (France) 17:50 028 ADULT PATIENTS WITH CAEBV-LIKE FEATURES: A DISTINCT SUBTYPE OF

EPSTEIN-BARR VIRUS POSITIVE T/NK-CELL LYMPHOPROLIFERATIVE DISORDER K. Kawamoto, Kurume (Japan) Auditorium (Lugano University)

NOVEL ANTI-LYMPHOMA DRUGS Chair: T.E. Witzig, Rochester, MN (USA)

17:00 029 PHARMACOLOGICAL ACTIVITY OF CB-103 IN HAEMATOLOGICAL MALIGNANCIES

– AN ORAL PAN-NOTCH INHIBITOR WITH A NOVEL MODE OF ACTION D. Weber, Basel (Switzerland) 17:10 030 ANTI-TUMOR ACTIVITY OF DARATUMUMAB, A NOVEL HUMAN ANTI CD38

MONOCLONAL ANTIBODY, IN IN VITRO AND IN VIVO MODELS OF B-CELL NON-HODGKIN LYMPHOMA

P. Pérez-Galán, Barcelona (Spain) 17:20 031 A NEW BCL-2 INHIBITOR (S55746/BCL201) AS MONOTHERAPY IN PATIENTS WITH

RELAPSED OR REFRACTORY NON-HODGKIN LYMPHOMA: PRELIMINARY RESULTS OF THE FIRST-IN-HUMAN STUDY

S. Le Gouill, Nantes (France) 17:30 032 PHASE I STUDY OF IPH4102, ANTI-KIR3DL2 MAB, IN RELAPSED/REFRACTORY

CUTANEOUS T-CELL LYMPHOMAS (CTCL): DOSE-ESCALATION SAFETY, BIOMARKER AND CLINICAL ACTIVITY RESULTS

Y.H. Kim, Stanford, CA (USA)

17:40 033 A PHASE 1 STUDY OF THE ANTI-CD37 ANTIBODY-DRUG CONJUGATE AGS67E IN ADVANCED LYMPHOID MALIGNANCIES. INTERIM RESULTS

A. Sawas, New York, NY (USA) 17:50 034 FIRST CLINICAL RESULTS OF ADCT-402, A NOVEL PYRROLOBENZODIAZEPINE-

BASED ANTIBODY DRUG CONJUGATE (ADC), IN RELAPSED/REFRACTORY B-CELL LINEAGE NHL

B.S. Kahl, St. Louis, MO (USA) Aula Magna (Lugano University)

CHEMOTHERAPY-FREE COMBINATIONS Chair: S.M. Smith, Chicago, IL (USA)

17:00 035 FINAL RESULTS OF CALGB 50803 (ALLIANCE): A PHASE 2 TRIAL OF

LENALIDOMIDE PLUS RITUXIMAB IN PATIENTS WITH PREVIOUSLY UNTREATED FOLLICULAR LYMPHOMA

P. Martin, New York, NY (USA) 17:10 036 L-MIND: MOR208 COMBINED WITH LENALIDOMIDE (LEN) IN PATIENTS WITH

RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (R-R DLBCL) – A SINGLE-ARM PHASE II STUDY

G. Salles, Lyon (France) 17:20 037 A PHASE II LYSA STUDY OF OBINUTUZUMAB COMBINED WITH LENALIDOMIDE

FOR RELAPSED OR REFRACTORY FOLLICULAR B-CELL LYMPHOMA F. Morschhauser, Lille (France) 17:30 038 PHASE IB STUDY OF CC-122 IN COMBINATION WITH OBINUTUZUMAB (GA101):

RELAPSED OR REFRACTORY (R/R) PATIENTS WITH B-CELL NON-HODGKIN LYMPHOMAS (NHL)

J.M. Michot, Villejuif (France) 17:40 039 PHASE I/IB DOSE ESCALATION AND EXPANSION OF IBRUTINIB AND BUPARLISIB

IN RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA, MANTLE CELL LYMPHOMA, AND FOLLICULAR LYMPHOMA

C. Batlevi, New York, NY (USA) 17:50 040 UPDATED RESULTS OF A MULTICENTER PHASE I/IB STUDY OF TGR-1202 IN

COMBINATION WITH IBRUTINIB IN PATIENTS WITH RELAPSED OR REFRACTORY MCL OR CLL

M.S. Davids, Boston, MA (USA) _____________________________________________________________________________________ Thursday, June 15, 2017 08:00 – 08:45

MEET THE PROFESSOR SESSIONS · 5 parallel sessions

Room A

MANAGEMENT OF AGGRESSIVE LYMPHOMAS IN VERY ELDERLY PATIENTS C. Thieblemont, Paris (France) repeated on Friday, June 16, in Aula Magna (Lugano University)

Room B and Marquee

CLINICAL APPLICATIONS OF GENOME STUDIES A. Younes, New York, NY (USA)

Cinema Corso RESPONSE-ADAPTED THERAPY IN HODGKIN LYMPHOMA

P.W.M. Johnson, Southampton (UK)

Auditorium (Lugano University)

ALCL AND PTCL: WHAT CAN PEDIATRIC AND ADULT ONCOLOGISTS LEARN FROM EACH OTHER? L. Brugières, Villejuif (France) and F. D'Amore, Aarhus (Denmark) offered only once

Aula Magna (Lugano University)

CHEMOTHERAPY-FREE TREATMENT OF INDOLENT LYMPHOMAS J.W. Friedberg, Rochester, NY (USA)

08:30 – 18:30 Marquee

POSTER SESSION

09:00 – 10:30

“CASE DISCUSSION” SESSIONS: California vs Germany 4 parallel sessions

Room A HODGKIN LYMPHOMA Chair: C. Moskowitz, New York, NY (USA) Discussants: R.H. Advani, Stanford vs P. Borchmann, Cologne Cinema Corso T-CELL LYMPHOMAS Chair: J.M. Vose, Omaha, NE (USA) Discussants: L.C. Pinter-Brown, Orange vs G. Wulf, Goettingen Auditorium PEDIATRIC AND ADOLESCENT LYMPHOMAS (Lugano University) Chair: W. Wössmann, Giessen (Germany)

Discussants: C. Bollard, Washington, DC vs B. Burkhardt, Muenster Aula Magna (Lugano University)

RADIOTHERAPY FOR LYMPHOMAS Chair: L. Specht, Copenhagen (Denmark) Discussants: R.T. Hoppe, Stanford vs G. Mikhaeel, London (UK)

09:00 – 10:30 Room B and Marquee

Abstract number

SESSION 1 – LYMPHOMA BIOLOGY Co-chairs: R. Küppers, Essen (Germany) and M.A. Shipp, Boston, MA (USA)

09:00 041 GB VIRUS-C (GBV-C) INFECTION AND RISK OF LYMPHOMA: A CASE-CONTROL

STUDY FROM NORTH AMERICA A. Fama, Rochester, MN (USA) 09:15 042 DRUG PERTURBATION BASED STRATIFICATION OF LYMPHOPROLIFERATIVE

DISORDERS S. Dietrich, Heidelberg (Germany) 09:30 043 ETS1 POSITIVELY REGULATES FAIM3 IN ACTIVATED B CELL-LIKE (ABC) DIFFUSE

LARGE B CELL LYMPHOMA (DLBCL) V. Priebe, Bellinzona (Switzerland) 09:45 044 NOTCH1 MUTATED CHRONIC LYMPHOCYTIC LEUKEMIA CELLS ARE

CHARACTERIZED BY A MYC-RELATED OVEREXPRESSION OF NUCLEOPHOSMIN-1 AND RIBOSOME ASSOCIATED COMPONENTS

F. Pozzo, Aviano (Italy) 10:00 045 ACTIVATION OF RHOA-VAV1 SIGNALING IN ANGIOIMMUNOBLASTIC T-CELL

LYMPHOMA M. Sakata-Yanagimoto, Ibaraki (Japan) 10:15 046 TARGETABLE FUSIONS OF THE FRK TYROSINE KINASE IN ALK-NEGATIVE

ANAPLASTIC LARGE CELL LYMPHOMA R.L. Boddicker, Rochester, MN (USA)

10:30 – 11:00 Marquee

COFFEE BREAK

11:00 – 12:00 Room A, B, Marquee, Cinema Corso and Aula Magna (Lugano University)

SESSION 2 – PRIMARY MEDIASTINAL B-CELL LYMPHOMA Co-chairs: A.J. Davies, Southampton (UK) and G.S. Nowakowski, Rochester, MN (USA)

11:00 047 MOLECULAR CLASSIFICATION OF PRIMARY MEDIASTINAL LARGE B CELL

LYMPHOMA USING FORMALIN-FIXED, PARAFFIN-EMBEDDED TISSUE SPECIMENS – AN LLMPP PROJECT

A. Mottok, Vancouver (Canada) 11:15 048 METABOLIC HETEROGENEITY OF BASELINE 18-FDG PET-CT SCAN PREDICTS

OUTCOME IN PRIMARY MEDIASTINAL B-CELL LYMPHOMA L. Ceriani, Bellinzona (Switzerland) 11:30 049 OUTCOMES OF ADULTS, ADOLESCENTS, AND CHILDREN WITH PRIMARY

MEDIASTINAL B-CELL LYMPHOMA TREATED WITH DOSE-ADJUSTED EPOCH-R THERAPY: A MULTICENTER RETROSPECTIVE ANALYSIS

L.G. Roth, New York, NY (USA) 11:45 050 EFFICACY AND SAFETY OF PEMBROLIZUMAB IN RELAPSED/REFRACTORY

PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA (rrPMBCL): INTERIM ANALYSIS OF THE KEYNOTE-170 PHASE 2 TRIAL

P.L. Zinzani, Bologna (Italy) 12:00 – 13:00 Marquee

LUNCH TIME AND POSTER VIEWING from 12:30 to 13:00 authors in front of their poster for discussion with attendees

13:00 – 13:45 Room A, B, Marquee, Cinema Corso and Aula Magna (Lugano University)

002

GIANNI BONADONNA MEMORIAL LECTURE · Chair: R. Dalla-Favera, New York, NY (USA) sponsored by American Association for Cancer Research – AACR GENETIC SIGNATURES AND TARGETABLE PATHWAYS IN LYMPHOID MALIGNANCIES M.A. Shipp, Boston, MA (USA)

13:15 – 16:45 Auditorium (Lugano University)

WORKSHOP - CONTEMPORARY LYMPHOMA TREATMENT: RADIATION THERAPY ISSUES Co-chairs: M.K. Gospodarowicz, Toronto (Canada) and J. Yahalom, New York, NY (USA) Organized by International Lymphoma Radiation Oncology Group – ILROG open to all 14-ICML attendees

MY INDICATIONS FOR RADIATION THERAPY IN THE PRIMARY TREATMENT OF HODGKIN AND NON HODGKIN LYMPHOMAS

13:15 A.K. Ng, Boston, MA (USA) 13:30 C. Thieblemont, Paris (France) 13:45 U. Ricardi, Turin (Italy) 14:00 Case oriented discussion: A.K. Ng, Boston (USA), C. Thieblemont, Paris (France),

U. Ricardi, Turin (Italy), J. Yahalom, New York, NY (USA) and M.K. Gospodarowicz, Toronto (Canada)

14:15 – 14:25 BREAK MY INDICATIONS FOR RADIATION THERAPY IN RELAPSED/REFRACTORY

HODGKIN AND NON HODGKIN LYMPHOMAS 14:25 J. Yahalom, New York, NY (USA) 14:40 G. Salles, Lyon (France) 14:55 G. Mikhaeel, London (UK)

15:10 Case oriented discussion: J. Yahalom, New York, NY (USA), G. Salles, Lyon (France),

G. Mikhaeel, London (UK) and M.K. Gospodarowicz, Toronto (Canada) 15:25 – 15:45 COFFEE BREAK - inside Auditorium (Lugano University) for workshop attendees APPROACHES TO REDUCE LATE EFFECTS OF LYMPHOMA TREATMENT 15:45 B.S. Dabaja, Houston, TX (USA): IS PROTON THERAPY THE ANSWER? 16:00 D. Hodgson, Toronto (Canada): STRATEGIES TO REDUCE THE RISK OF SECOND

MALIGNANCIES 16:15 L. Specht, Copenhagen (Denmark): STRATEGIES TO REDUCE THE RISK OF

CARDIOVASCULAR LATE EFFECTS 16:30 Discussion: B.S. Dabaja, Houston, TX (USA), D. Hodgson, Toronto (Canada), L. Specht,

Copenhagen (Denmark), J. Yahalom, New York, NY (USA) and M.K. Gospodarowicz, Toronto (Canada)

13:45 – 15:15 Room A, B, Marquee, Cinema Corso and Aula Magna (Lugano University)

SESSION 3 – HODGKIN LYMPHOMA Co-chairs: V. Diehl, Cologne (Germany) and A. Pavlovsky, Buenos Aires (Argentina)

13:45 051 RESTORE & TARGET: A CONCEPTUALLY NOVEL TREATMENT APPROACH TO

CLASSICAL HODGKIN’S LYMPHOMA C. Schmitt, Berlin (Germany) 14:00 052 GENOTYPING OF CLASSICAL HODGKIN LYMPHOMA ON THE LIQUID BIOPSY A. Bruscaggin, Bellinzona (Switzerland) 14:15 053 eBEACOPP WITH OR WITHOUT RITUXIMAB IN INTERIM-PET-POSITIVE

ADVANCED-STAGE HODGKIN LYMPHOMA: UPDATED RESULTS OF THE INTERNATIONAL, RANDOMIZED PHASE 3 GHSG HD18 TRIAL

P. Borchmann, Cologne (Germany) 14:30 054 RESPONSE-ADJUSTED THERAPY FOR ADVANCED HODGKIN LYMPHOMA

(RATHL) TRIAL: LONGER FOLLOW UP CONFIRMS EFFICACY OF DE-ESCALATION AFTER A NEGATIVE INTERIM PET SCAN (CRUK/07/033)

J. Trotman, Concord (Australia) 14:45 055 BLOCKADE OF THE PD-1 CHECKPOINT WITH ANTI–PD-L1 ANTIBODY AVELUMAB

IS SUFFICIENT FOR CLINICAL ACTIVITY IN RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA (cHL)

R. Chen, Duarte, CA (USA) 15:00 056 COMBINED RISK OF SECOND MALIGNANT NEOPLASMS AND CARDIOVASCULAR

DISEASE IN LONG-TERM HODGKIN LYMPHOMA SURVIVORS B.M. Aleman, Amsterdam (The Netherlands) 15:15 – 15:30 Marquee, Cinema Corso and Aula Magna (Lugano University)

COFFEE BREAK

15:30 – 17:00 2 parallel sessions 15:30 – 17:00 Room A, Cinema Corso and Aula Magna (Lugano University)

SESSION 4 – TARGETING THE BCR PATHWAYS Co-chairs: J.F. Seymour, Melbourne (Australia) and C. Thieblemont, Paris (France)

15:30 057 CLINICAL OUTCOMES AND MOLECULAR CHARACTERIZATION FROM A PHASE II

STUDY OF COPANLISIB IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA

G. Lenz, Muenster (Germany) 15:45 058 DYNAMO: A PHASE 2 STUDY DEMONSTRATING THE CLINICAL ACTIVITY OF

DUVELISIB IN PATIENTS WITH DOUBLE-REFRACTORY INDOLENT NON-HODGKIN LYMPHOMA

P.L. Zinzani, Bologna (Italy) 16:00 059 BRUTON’S TYROSINE KINASE (BTK) INHIBITOR BGB-3111 DEMONSTRATES HIGH

VERY GOOD PARTIAL RESPONSE (VGPR) RATE IN PATIENTS WITH WALDENSTRÖM MACROGLOBULINEMIA (WM)

J. Trotman, Concord (Australia) 16:15 060 IBRUTINIB IN RELAPSE OR REFRACTORY PRIMARY CNS AND VITREO-RETINAL

LYMPHOMA. RESULTS OF THE PRIMARY END-POINT OF THE LOC PHASE II STUDY FROM THE LYSA AND THE FRENCH LOC NETWORK

C. Soussain, Saint-Cloud (France) 16:30 061 TAK-659, AN INVESTIGATIONAL REVERSIBLE DUAL SYK/FLT-3 INHIBITOR, IN

PATIENTS WITH LYMPHOMA: UPDATED RESULTS FROM DOSE-ESCALATION AND EXPANSION COHORTS OF A PHASE 1 STUDY

J. Kaplan, Chicago, IL (USA) 16:45 062 THE DUAL SYK/JAK INHIBITOR CERDULATINIB DEMONSTRATES RAPID TUMOR

RESPONSES IN A PHASE 2 STUDY IN PATIENTS WITH RELAPSED/REFRACTORY B-CELL MALIGNANCIES

P.A. Hamlin, Basking Ridge, NJ (USA) 15:30 – 17:00 Room B and Marquee

SESSION 5 – T-CELL LYMPHOMAS Co-chairs: K. Tobinai, Tokyo (Japan) and J.M. Vose, Omaha, NE (USA)

15:30 063 GENE EXPRESSION PROFILING USING A RTMLPA ASSAY ALLOWS FOR AN ACCURATE

CLASSIFICATION OF PERIPHERAL T-CELL LYMPHOMA AND HIGHLIGHTS NOVEL SUBGROUPS WITHIN PTCLs-NOS

P. Ruminy, Rouen (France) 15:45 064 CHOP VERSUS GEM-P IN THE FIRST-LINE TREATMENT OF T-CELL LYMPHOMA:

INITIAL RESULTS OF THE UK NRCI PHASE II RANDOMISED CHEMO-T TRIAL M. Gleeson, Sutton (UK) 16:00 065 ROLE OF UP-FRONT AUTOLOGOUS STEM CELL TRANSPLANTATION IN

PERIPHERAL T-CELL LYMPHOMA: A PROPENSITY SCORE MATCHING ANALYSIS OF PATIENTS FROM LYSA CENTERS

G. Fossard, Pierre Bénite (France) 16:15 066 BRENTUXIMAB VEDOTIN VS PHYSICIAN’S CHOICE IN CTCL PATIENTS FROM THE

PHASE 3 ALCANZA STUDY: ANALYSIS OF OUTCOMES BY CD30 EXPRESSION Y.H. Kim, Stanford, CA (USA)

16:30 067 IMPROVED SURVIVAL OUTCOMES FOR PATIENTS WITH EXTRA-NODAL NK/T LYMPHOMA; DATA FROM 140 PATIENTS PROSPECTIVELY REGISTERED IN THE INTERNATIONAL T-CELL PROJECT

C.P. Fox, Nottingham (UK) 16:45 068 GAD-M REGIMEN FOR NEWLY DIAGNOSED EXTRANODAL NK/T CELL LYMPHOMA:

ANALYSIS OF EFFICACY AND SAFETY FROM PHASE II STUDY (NCT 01991158) Z. Li, Guang Zhou (China) 17:00 -17:15 BREAK 17:15 – 18:15

“FOCUS ON…” SESSIONS 5 parallel sessions

Room A TARGETING CD30 IN HODGKIN LYMPHOMA Chair: A. Engert, Cologne (Germany) 17:15 069 RESULTS OF A PHASE II STUDY OF BRENTUXIMAB VEDOTIN IN THE FIRST LINE

TREATMENT OF HODGKIN LYMPHOMA PATIENTS CONSIDERED UNSUITABLE FOR STANDARD CHEMOTHERAPY (BREVITY)

A. Gibb, Manchester (UK) 17:25 070 BRENTUXIMAB VEDOTIN CONSOLIDATION TO REDUCE RADIATION USE IN

PATIENTS WITH LIMITED STAGE NON-BULKY HODGKIN LYMPHOMA: AN UPDATE FROM A PHASE 2 CLINICAL TRIAL

S.I. Park, Charlotte, NC (USA) 17:35 071 RESULTS OF A MULTICENTRE UK-WIDE STUDY EVALUATING THE EFFICACY OF

BRENTUXIMAB VEDOTIN IN RELAPSED, REFRACTORY CLASSICAL HODGKIN LYMPHOMA IN THE PRE-TRANSPLANT NAIVE SETTING

T.A. Eyre, Oxford (UK) 17:45 072 BRENTUXIMAB VEDOTIN FOR RELAPSED HODGKIN LYMPHOMA AFTER

ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION: A RETROSPECTIVE STUDY OF THE EBMT LYMPHOMA WORKING PARTY

A. Bazarbachi, Beirut (Lebanon) 17:55 073 SAFETY AND EFFICACY OF COMBINATION OF BRENTUXIMAB VEDOTIN AND

NIVOLUMAB IN RELAPSED / REFRACTORY HODGKIN LYMPHOMA: A TRIAL OF THE ECOG-ACRIN CANCER RESEARCH GROUP (E4412)

C.S. Diefenbach, New York, NY (USA) 18:05 074 INTERIM RESULTS FROM A PHASE 1/2 STUDY OF BRENTUXIMAB VEDOTIN IN

COMBINATION WITH NIVOLUMAB IN PATIENTS WITH RELAPSED OR REFRACTORY HODGKIN LYMPHOMA

A.F. Herrera, Duarte, CA (USA) Room B NOVEL ANTI-LYMPHOMA STRATEGIES and Marquee Chair: P.W.M. Johnson, Southampton (UK) 17:15 075 CLARITHROMYCIN AS A “REPURPOSING DRUG” AGAINST LYMPHOMAS: SAFETY

AND EFFICACY PROFILES IN 55 PATIENTS WITH EXTRANODAL MARGINAL ZONE LYMPHOMA (EMZL)

A.J. Ferreri, Milan (Italy) 17:25 076 A PHASE 1 STUDY OF PRALATREXATE PLUS ROMIDEPSIN REVEALS MARKED

ACTIVITY IN PATIENTS WITH RELAPSED OR REFRACTORY (R/R) PERIPHERAL T-CELL LYMPHOMA (PTCL)

J.E. Amengual, New York, NY (USA)

17:35 077 CANADIAN CANCER TRIALS GROUP (CCTG) LY.17: A RANDOMIZED PHASE II STUDY EVALUATING NOVEL SALVAGE THERAPY PRE-AUTOLOGOUS STEM CELL TRANSPLANT (ASCT) IN RELAPSED/REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA (RR-DLBCL) - OUTCOME OF IBRUTINIB + R-GDP

J. Kuruvilla, Kingston (Canada) 17:45 078 EFFECT OF ADDING IDELALISIB TO FRONTLINE OFATUMUMAB PLUS EITHER

CHLORAMBUCIL OR BENDAMUSTINE IN LESS FIT PATIENTS WITH CLL: PRELIMINARY RESULTS FROM THE NCRI RIALTO TRIAL

A. Pettitt, Liverpool (UK) 17:55 079 VENETOCLAX (VEN), BENDAMUSTINE (B) AND RITUXIMAB (R) IN PATIENTS (PTS)

WITH RELAPSED OR REFRACTORY (R/R) NON-HODGKIN LYMPHOMA (NHL): FINAL RESULTS OF A PHASE I STUDY

L.J. Swinnen, Baltimore, MD (USA) 18:05 080 POLA-R-CHP: POLATUZUMAB VEDOTIN COMBINED WITH RITUXIMAB,

CYCLOPHOSPHAMIDE, DOXORUBICIN, PREDNISONE FOR PATIENTS WITH PREVIOUSLY UNTREATED DIFFUSE LARGE B-CELL LYMPHOMA

H. Tilly, Rouen (France) Cinema Corso CLINICO-GENETIC RISK MODELS Chair: P. Gaulard, Créteil (France) 17:15 081 APPLICATION OF A GENE EXPRESSION-BASED MODEL IN COMBINATION WITH

FDG-PET IMAGING TO PREDICT TREATMENT RESPONSE IN ADVANCED HODGKIN LYMPHOMA IN THE RATHL STUDY (CRUK/07/033)

C.H. Burton, Leeds (UK) 17:25 082 THE 23-GENE GENE EXPRESSION-BASED ASSAY DOES NOT PREDICT INTERIM

PET SCAN RESULTS AFTER ABVD IN ADVANCED STAGE CLASSICAL HODGKIN LYMPHOMA IN THE US INTERGROUP S0816 TRIAL

D.W. Scott, Vancouver (Canada) 17:35 083 GENE MUTATIONS AND COPY NUMBER ALTERATIONS (CNA) PREDICT FOR

EARLY FAILURE IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) TREATED WITH R-CHOP

I. Dlouhy, Barcelona (Spain) 17:45 084 KMT2D AND TP53 MUTATIONS PREDICT POOR PFS AND OS IN MANTLE CELL

LYMPHOMA RECEIVING HIGH-DOSE THERAPY AND ASCT: THE FONDAZIONE ITALIANA LINFOMI (FIL) MCL0208 PHASE III TRIAL

S. Ferrero, Turin (Italy) 17:55 085 BASELINE CIRCULATING CELL-FREE DNA LOAD IS RELATED TO, BUT ADDS

PROGNOSTIC VALUE TO METABOLIC TUMOR BURDEN MEASURED BY FDG PET/CT IN FOLLICULAR LYMPHOMA

M.H. Delfau-Larue, Creteil (France) 18:05 086 EVALUATION OF CLINICOGENETIC RISK MODELS FOR OUTCOME OF

FOLLICULAR LYMPHOMA PATIENTS IN THE PRIMA TRIAL S. Huet, Pierre Bénite (France) Auditorium (Lugano University)

ONGOING TRIALS Chair: M. Dreyling, Munich (Germany)

17:15 OT01 ROBUST: PHASE III RANDOMIZED STUDY OF LENALIDOMIDE/R-CHOP VS

PLACEBO/R-CHOP IN UNTREATED ABC-TYPE DIFFUSE LARGE B-CELL LYMPHOMA AND FEASIBILITY OF CELL OF ORIGIN SUBTYPING

A. Chiappella, Turin (Italy)

17:25 OT02 PHASE II STUDY OF DURVALUMAB (ANTI–PD-L1) COMBINED WITH EITHER R-CHOP OR LENALIDOMIDE AND R-CHOP IN PREVIOUSLY UNTREATED, HIGH-RISK DIFFUSE LARGE B-CELL LYMPHOMA

U. Jäger, Vienna (Austria) 17:35 OT03 CHECKMATE 647: A PHASE 2, OPEN-LABEL STUDY OF NIVOLUMAB IN

RELAPSED/REFRACTORY PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA OR RELAPSED/REFRACTORY PRIMARY TESTICULAR LYMPHOMA

L. Nayak, Boston, MA (USA) 17:45 OT04 MCL-R2 ELDERLY: A PHASE III STUDY OF THE EUROPEAN MCL NETWORK

ASSESSING EFFICACY OF ALTERNATING IMMUNOCHEMOTHERAPY (R-CHOP / R-HAD) AND A RITUXIMAB-LENALIDOMIDE MAINTENANCE

V. Ribrag, Villejuif (France) 17:55 OT05 PHASE 3 STUDY OF IBRUTINIB IN COMBINATION WITH VENETOCLAX IN

PATIENTS WITH RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA (MCL) C.S. Tam, Melbourne (Australia) 18:05 OT06 A HEAD-TO-HEAD PHASE 3 STUDY COMPARING BGB-3111 AND IBRUTINIB IN

PATIENTS WITH WALDENSTRÖM MACROGLOBULINEMIA C. Buske, Ulm (Germany) Aula Magna (Lugano University)

LYMPHOMA IN THE ELDERLY Chair: U. Vitolo, Turin (Italy)

17:15 087 HIGHER AGE IS ASSOCIATED WITH INCREASED MUTATIONAL BURDEN BUT

DOES NOT IMPACT TREATMENT EFFICACY IN FOLLICULAR LYMPHOMA S. Alig, Munich (Germany) 17:25 088 LOW NK CELL COUNT AT DIAGNOSIS IS ASSOCIATED WITH SHORTER PFS IN

ELDERLY PATIENTS WITH DLBCL TREATED WITH RCHOP AND RANDOMIZED FOR LENALIDOMIDE MAINTENANCE. A LYSA STUDY

M.H. Delfau-Larue, Creteil (France) 17:35 089 CHARACTERISTICS, TREATMENT, AND OUTCOMES OF ≥ 80 YEAR OLD PATIENTS

WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) ENROLLED TO PROSPECTIVE TRIALS OF THE GERMAN CLL STUDY GROUP

O. Al-Sawaf, Cologne (Germany) 17:45 090 UNMET MEDICAL NEEDS IN HODGKIN LYMPHOMA WITH SPECIAL FOCUS ON THE

ELDERLY – A POPULATION-BASED STUDY OF PATIENTS DIAGNOSED IN SWEDEN 1973-2014

M. Björkholm, Stockholm (Sweden) 17:55 091 TREATMENT STRATEGIES AND OUTCOMES IN DIFFUSE LARGE B-CELL

LYMPHOMA OF THE ELDERLY: A DANISH POPULATION-BASED COHORT STUDY OF 1,011 PATIENTS

M.B. Juul, Odense (Denmark) 18:05 092 REMARC STUDY: CORRELATION OF LYMPHOMA PD AND DEATH AND HEALTH-

RELATED QOL WITH MAINTENANCE LENALIDOMIDE VS PLACEBO IN ELDERLY DLBCL PATIENT RESPONDERS TO R-CHOP

C. Thieblemont, Paris (France)

______________________________________________________________________________________ Friday, June 16, 2017

08:00 – 08:45

MEET THE PROFESSOR SESSIONS · 5 parallel sessions

Room A

ROLE AND TIMING OF NEW DRUGS IN CLL M. Hallek, Cologne (Germany)

Room B and Marquee

THE MULTIPLE FACETS OF MARGINAL ZONE LYMPHOMAS M. Raderer, Vienna (Austria)

Cinema Corso THE 2016 UPDATED WHO CLASSIFICATION OF LYMPHOID NEOPLASIAS

L. Quintanilla-Martinez, Tuebingen (Germany) Auditorium (Lugano University)

LATE SEQUELAE IN HODGKIN LYMPHOMA SURVIVORS F.E. Van Leeuwen, Amsterdam (The Netherlands) offered only once

Aula Magna (Lugano University)

MANAGEMENT OF AGGRESSIVE LYMPHOMAS IN VERY ELDERLY PATIENTS C. Thieblemont, Paris (France)

08:30 – 18:30 Marquee

POSTER SESSION

09:00 – 10:30

“CASE DISCUSSION” SESSIONS: California vs Germany 4 parallel sessions

Room A AGGRESSIVE LYMPHOMAS Chair: S. Le Gouill, Nantes (France) Discussants: S. De Vos, Santa Monica vs G. Lenz, Muenster Cinema Corso INDOLENT LYMPHOMAS Chair: A. Lopez-Guillermo, Barcelona (Spain) Discussants: T. J. Kipps, La Jolla vs M. Dreyling, Munich Auditorium (Lugano University)

CLL Chair: J.G. Gribben, London (UK) Discussants: S.M. O’Brien, Orange vs S. Stilgenbauer, Ulm

Aula Magna (Lugano University)

DIFFICULT PATHOLOGICAL CASES Chair: M. Ghielmini, Bellinzona (Switzerland) Presenters: E. Campo, Barcelona (Spain), S. Dirnhofer, Basel (Switzerland), L. Quintanilla-Martinez, Tuebingen (Germany) Discussants: S.T. Rosen, Duarte vs U. Dührsen, Essen

09:00 – 10:30 Room B and Marquee

SESSION 6 – LYMPHOMA GENOMICS Co-chairs: A. Melnick, New York, NY (USA) and W.-L. Zhao, Shanghai (China)

09:00 093 A SINGLE-CELL BASED MODEL EXPLAINS PATTERNS OF CLONAL EVOLUTION

IN PRIMARY AND RELAPSED FOLLICULAR LYMPHOMA M. Löffler, Leipzig (Germany) 09:15 094 FULL TRANSCRIPTOME SEQUENCING OF SORTED HODGKIN AND REED-

STERNBERG CELLS REVEALS PLASMACYTIC DIFFERENTIATION, INSIGHTS INTO MECHANISMS OF ONCOGENESIS AND IMMUNE EVASION

M. Roshal, New York, NY (USA)

09:30 095 PROFILING OF DNA METHYLATION IN EPIDEMIOLOGICAL AND CLINCAL SUBGROUPS OF BURKITT LYMPHOMA IN THE FRAMEWORK OF THE MMML, ICGC AND BLUEPRINT CONSORTIA

R. Wagener, Ulm (Germany) 09:45 096 MUTATIONAL SIGNATURES IN GERMINAL CENTER DERIVED B-CELL

LYMPHOMAS FROM ADULT PATIENTS ANALYZED IN THE ICGC MMML-SEQ CONSORTIUM

D. Huebschmann, Heidelberg (Germany) 10:00 097 CROSS-PLATFORM VALIDATION OF GENE EXPRESSION PROFILING (GEP)

BASED CELL OF ORIGIN (COO) CLASSIFICATION IN A CLINICAL LABORATORY SETTING

S. Barrans, Leeds (UK) 10:15 098 THE LANDSCAPE OF SOMATIC MUTATIONS OF PRIMARY CUTANEOUS DIFFUSE

LARGE B-CELL LYMPHOMA, LEG-TYPE F. Jardin, Rouen (France) 10:30 – 10:50 Marquee

COFFEE BREAK

10:50 – 12:05 Room A, B, Marquee, Cinema Corso and Aula Magna (Lugano University)

SESSION 7 – ADVANCES IN CLL Co-chairs: N. Chiorazzi, Manhasset, NY (USA) and B. Eichhorst, Cologne (Germany)

10:50 099 INSIDE-OUT VLA-4 INTEGRIN ACTIVATION IS MAINTAINED IN IBRUTINIB-

TREATED CHRONIC LYMPHOCYTIC LEUKEMIA EXPRESSING CD49d: CLINICAL RELEVANCE

E. Tissino, Aviano (Italy) 11:05 100 INTEGRATED ANALYSIS: OUTCOMES OF IBRUTINIB-TREATED PATIENTS WITH

CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LEUKEMIA (CLL/SLL) WITH HIGH-RISK PROGNOSTIC FACTORS

T.J. Kipps, La Jolla, CA (USA) 11:20 101 UBLITUXIMAB AND IBRUTINIB FOR PREVIOUSLY TREATED GENETICALLY HIGH-

RISK CHRONIC LYMPHOCYTIC LEUKEMIA: RESULTS OF THE GENUINE PHASE 3 STUDY

A. Mato, Philadelphia, PA (USA) 11:35 102 CHEMO-FREE TRIPLET COMBINATION OF TGR-1202, UBLITUXIMAB, AND

IBRUTINIB IS WELL TOLERATED AND HIGHLY ACTIVE IN PATIENTS WITH ADVANCED CLL AND NHL

L.J. Nastoupil, Houston, TX (USA) 11:50 103 SAFETY AND ACTIVITY OF THE HIGHLY SPECIFIC BTK INHIBITOR, BGB-3111

PLUS OBINUTUZUMAB IN PATIENTS (PTS) WITH FOLLICULAR LYMPHOMA (FL) AND CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)

C.S. Tam, Melbourne (Australia) 12:05 – 13:00 Marquee

LUNCH TIME AND POSTER VIEWING from 12:30 to 13:00 authors in front of their poster for discussion with attendees

13:00 – 13:45 Room A, B, Marquee, Cinema Corso and Aula Magna

JOHN ULTMANN MEMORIAL LECTURE · Chair: E. Campo, Barcelona (Spain) sponsored by European School of Oncology – ESO

(Lugano University)

003 GENOMES IN TRANSIT: WHAT MULTI-OMICS CAN TELL US ON LYMPHOMAS R. Siebert, Ulm (Germany)

3 parallel sessions 13:45 – 15:15 Room A, B, Marquee and Cinema Corso

SESSION 8 – FOLLICULAR LYMPHOMA Co-chairs: B.S. Kahl, St. Louis, MO (USA) and E. Kimby, Stockholm (Sweden)

13:45 104 GENE-EXPRESSION PROFILING PREDICTS DISEASE PROGRESSION IN

FOLLICULAR LYMPHOMA S. Huet, Pierre Bénite (France) 14:00 105 THE RISK OF TRANSFORMATION OF FOLLICULAR LYMPHOMA “TRANSFORMED”

BY RITUXIMAB. THE ARISTOTLE STUDY PROMOTED BY THE EUROPEAN LYMPHOMA INSTITUTE

M. Federico, Modena (Italy) 14:15 106 PROGNOSTIC MODEL FOR HIGH TUMOR BURDEN FOLLICULAR LYMPHOMA

INCLUDING BASELINE TOTAL METABOLIC TUMOR VOLUME AND END INDUCTION PET: A POOLED ANALYSIS FROM LYSA AND FIL TRIALS

A. Cottereau, Paris (France) 14:30 107 IMMUNOCHEMOTHERAPY WITH OBINUTUZUMAB OR RITUXIMAB IN

PREVIOUSLY UNTREATED FOLLICULAR LYMPHOMA IN THE RANDOMISED PHASE III GALLIUM STUDY: ANALYSIS BY CHEMOTHERAPY REGIMEN

W. Hiddemann, Munich (Germany) 14:45 108 COPANLISIB IN PATIENTS WITH RELAPSED OR REFRACTORY INDOLENT B-

CELL LYMPHOMA (CHRONOS-1) M. Dreyling, Munich (Germany) 15:00 109 HIGH RESPONSE RATES WITH PEMBROLIZUMAB IN COMBINATION WITH

RITUXIMAB IN PATIENTS WITH RELAPSED FOLLICULAR LYMPHOMA: INTERIM RESULTS OF AN ON OPEN-LABEL, PHASE II STUDY

L.J. Nastoupil, Houston, TX (USA) 14:15 – 17:15 Auditorium (Lugano University)

IBSA FOUNDATION SPECIAL FORUM - BASIC MECHANISMS OF CANCER IMMUNOTHERAPY Chair: A. Alimonti, Bellinzona (Switzerland) Organized by IBSA Foundation for Scientific Research open to all 14-ICML attendees, appreciated pre-registration at www.ibsafoundation.org (free session)

14:15 WELCOME S. Misiti, Lugano (Switzerland) 14:20 INTRODUCTION A. Alimonti, Bellinzona (Switzerland) 14:30 IMMUNOTHERAPY HAS COME OF AGE R. Levy, Stanford, CA (USA) 15:00 IMMUNOGENIC CELL DEATH: EXPLAINING THE SUCCESS OF CANCER

THERAPIES G. Kroemer, Paris (France) 15:30 – 16:00 COFFEE BREAK - inside Auditorium (Lugano University) for attendees

16:00 WHY THE IMMUNE RESPONSE IN LYMPHOMA IS INADEQUATE F. Caligaris-Cappio, Milan (Italy) 16:30 PRE-CLINICAL DEVELOPMENT OF NOVEL COMBINATORIAL THERAPIES

AGAINST MYC/BCL2 DOUBLE-HIT LYMPHOMA B. Amati, Milan (Italy) 14:15 – 17:05 Aula Magna (Lugano University)

UCLI-ICML JOINT SESSION - NATURAL KILLER / T-CELL (NK/T-CELL) LYMPHOMA Co-chairs: J.M. Vose, Omaha, NE (USA), J. Zhu, Beijing (China) and Y.-K. Shi, Beijing (China) Organized in collaboration with Union of Chinese Lymphoma Investigators - UCLI

14:15 110 NON-CANONICAL ROLE OF EZH2 IN NK / T-CELL LYMPHOMA W.-J. Chng, Singapore (Singapore) 14:30 111 EBV-ASSOCIATED NODAL T AND NK-CELL LYMPHOMA SHOWS DISTINCT

MOLECULAR SIGNATURE AND COPY NUMBER CHANGES W.-J. Chng, Singapore (Singapore) 14:45 112 NK/T-CELL LYMPHOMA: WHEN PATIENTS MEET OMICS W.-L. Zhao, Shanghai (China) 15:00 113 TREATMENT OF EXTRANODAL NK/T-CELL LYMPHOMA, NASAL TYPE (ENKTL) W.S. Kim, Seoul (South Korea) 15:15 – 15:35 COFFEE BREAK - inside Aula Magna (Lugano University) for attendees 15:35 114 FIRST-LINE L-ASPARAGINASE-BASED CHEMOTHERAPY PLUS RADIOTHERAPY

IS ACTIVE IN STAGE I/II EXTRANODAL NK/T-CELL LYMPHOMA: RESULTS FROM PEKING UNIVERSITY CANCER HOSPITAL

Y.-Q. Song, Beijing (China) 15:50 115 CURRENT TREATMENT FOR NK/T CELL LYMPHOMA: SUN YAT-SEN UNIVERSITY

CANCER CENTER EXPERIENCE, CHINA H.-Q. Huang, Guangzhou (China) 16:05 116 MOLECULAR CHARACTERIZATION OF EXTRANODAL NATURAL KILLER (NK)/T-

CELL LYMPHOMAS, NASAL TYPE FROM LATIN AMERICA L. Quintanilla-Martinez, Tuebingen (Germany) 16:20 117 NK/T-CELL LYMPHOMA, THE FRENCH EXPERIENCE A. Jaccard, Limoges (France) 16:35 COMMENTS M. Federico, Modena (Italy), W.-Q. Jiang, Guangzhou (China) and X.-P. Lu, Shenzhen

(China) 15:15 – 15:35 Marquee, Cinema Corso

COFFEE BREAK

15:35 – 15:50 Room A, B, Marquee and Cinema Corso

DESIGN OF FUTURE CLINICAL TRIALS: REPORT OF THE 14-ICML WORKSHOP Co-chairs: M.K. Gospodarowicz, Toronto (Canada) and E. Zucca, Bellinzona (Switzerland) A. Younes, New York, NY (USA)

15:50 – 17:20 Room A, B, Marquee and Cinema Corso

SESSION 9 – AGGRESSIVE LYMPHOMAS Co-chairs: M.K. Gospodarowicz, Toronto (Canada) and E. Zucca, Bellinzona (Switzerland)

15:50 118 LONG-TERM SURVIVAL AND LOSS IN EXPECTANCY OF LIFE IN A POPULATION-

BASED COHORT OF 7114 PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA K.E. Smedby, Solna (Sweden) 16:05 119 R-CHOP +/-RADIOTHERAPY IN NON-BULKY LIMITED-STAGE DIFFUSE LARGE B-

CELL LYMPHOMA (DLBCL): FINAL RESULTS OF THE PROSPECTIVE RANDOMIZED PHASE III 02-03 TRIAL FROM THE LYSA/GOELAMS

T. Lamy, Rennes (France) 16:20 120 RADIOTHERAPY TO BULKY DISEASE PET-NEGATIVE AFTER

IMMUNOCHEMOTHERAPY CAN BE SPARED IN ELDERLY DLBCL PATIENTS: RESULTS OF A PLANNED INTERIM ANALYSIS OF THE FIRST 187 PATIENTS WITH BULKY DISEASE TREATED IN THE OPTIMAL>60 STUDY OF THE DSHNHL

M. Pfreundschuh, Homburg (Germany) 16:35 121 DIFFERENTIAL EFFICACY OF BORTEZOMIB IN SUBTYPES OF DIFFUSE LARGE

B-CELL LYMPHOMA (DLBL): A PROSPECTIVE RANDOMISED STUDY STRATIFIED BY TRANSCRIPTOME PROFILING: REMoDL-B

A.J. Davies, Southampton (UK) 16:50 122 PROGNOSTIC IMPACT OF BCL2 AND MYC EXPRESSION AND TRANSLOCATION

IN UNTREATED DLBCL: RESULTS FROM THE PHASE III GOYA STUDY U. Vitolo, Turin (Italy) 17:05 123 RISK-ADAPTED THERAPY IN ADULTS WITH BURKITT LYMPHOMA: UPDATED

RESULTS OF A MULTICENTER PROSPECTIVE PHASE II STUDY OF DA-EPOCH-R K. Dunleavy, Bethesda, MD (USA) 17:30 – 18:45 Marquee

FAREWELL APERO

______________________________________________________________________________________ Saturday, June 17, 2017 08:00 – 10:30 Room 156 (Lugano University)

SPECIAL SESSION - CONTOURING IN MODERN LYMPHOMA RADIOTHERAPY PLANNING A.K. Berthelsen, Copenhagen (Denmark) and L. Specht, Copenhagen (Denmark) Organized by International Lymphoma Radiation Oncology Group - ILROG and European Society for Radiotherapy and Oncology – ESTRO Compulsory pre-registration up to 30 attendees at registration@lymphcon.ch (fee CHF 50.-)

08:30 – 10:00

2 parallel sessions

Room A SESSION 10 – IMMUNOTHERAPIES Co-chairs: R. Levy, Stanford, CA (USA) and D.G. Maloney, Seattle, WA (USA)

08:30 124 CD27 STIMULATION ENHANCES CD20 MAB THERAPY THROUGH ACTIVATION OF

INNATE IMMUNITY S.H. Lim, Southampton (UK) 08:45 125 NIVOLUMAB FOR RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA

AFTER AUTOLOGOUS TRANSPLANT: FULL RESULTS AFTER EXTENDED FOLLOW-UP OF THE PHASE 2 CHECKMATE 205 TRIAL

M. Fanale, Houston, TX (USA)

09:00 126 PEMBROLIZUMAB MONOTHERAPY IN PATIENTS WITH PRIMARY REFRACTORY

CLASSICAL HODGKIN LYMPHOMA: SUBGROUP ANALYSIS OF THE PHASE 2 KEYNOTE-087 STUDY

P.L. Zinzani, Bologna (Italy) 09:15 127 A PHASE Ib STUDY EVALUATING THE SAFETY AND CLINICAL ACTIVITY OF

ATEZOLIZUMAB COMBINED WITH OBINUTUZUMAB IN PATIENTS WITH RELAPSED OR REFRACTORY NON-HODGKIN LYMPHOMA (NHL)

M.L. Palomba, New York, NY (USA) 09:30 128 HIGH CR RATES IN RELAPSED/REFRACTORY (R/R) AGGRESSIVE B-NHL TREATED

WITH THE CD19-DIRECTED CAR T CELL PRODUCT JCAR017 (TRANSCEND NHL 001)

J. Abramson, Boston, MA (USA) 09:45 129 A PHASE I TRIAL OF 19-28Z CAR-T CELLS POST-HIGH DOSE THERAPY AND

AUTOLOGOUS TRANSPLANTATION (HDT-ASCT) FOR RELAPSED AND REFRACTORY (R/R) B-CELL NON-HODGKIN LYMPHOMA (B-NHL)

C. Sauter, New York, NY (USA) Room B SESSION 11 – MANTLE CELL LYMPHOMA

Co-chairs: U. Novak, Bern (Switzerland) and G. Salles, Lyon (France) 08:30 130 P53 BUT NOT SOX11 IHC HAS PROGNOSTIC VALUE INDEPENDENT OF MIPI AND

KI-67 IN PROSPECTIVE TRIALS OF THE EUROPEAN-MCL NETWORK M. Dreyling, Munich (Germany) 08:45 131 FIRST-LINE TREATMENT OF INHL OR MCL PATIENTS WITH BR OR R-CHOP/R-CVP:

RESULTS OF THE BRIGHT 5-YEAR FOLLOW-UP STUDY T. Hawkins, Auckland (New Zealand) 09:00 132 FIRST LINE TREATMENT BY THE RIBVD REGIMEN ELICITS HIGH CLINICAL AND

MOLECULAR RESPONSE RATES AND PROLONGED SURVIVAL IN ELDERLY MCL PATIENTS; FINAL RESULTS OF A LYSA GROUP TRIAL

R. Gressin, Grenoble (France) 09:15 133 IBRUTINIB-RITUXIMAB FOLLOWED BY REDUCED CHEMO-IMMUNOTHERAPY

CONSOLIDATION IN YOUNG, NEWLY DIAGNOSED MANTLE CELL LYMPHOMA PATIENTS: A WINDOW OF OPPORTUNITY TO REDUCE CHEMO

M.L. Wang, Houston, TX (USA) 09:30 134 IBRUTINIB VS TEMSIROLIMUS: THREE-YEAR FOLLOW-UP OF PATIENTS WITH

PREVIOUSLY TREATED MANTLE CELL LYMPHOMA FROM THE PHASE 3, INTERNATIONAL, RANDOMIZED, OPEN-LABEL RAY STUDY

S. Rule, Plymouth (UK) 09:45 135 COMBINATION IBRUTINIB (IBR) AND VENETOCLAX (VEN) FOR THE TREATMENT

OF MANTLE CELL LYMPHOMA (MCL): PRIMARY ENDPOINT ASSESSMENT OF THE PHASE 2 AIM STUDY

C.S. Tam, Melbourne (Australia) 10:00 – 10:15 BREAK 10:15 – 11:15 Room A and B

SESSION 12 – MARGINAL ZONE LYMPHOMA Co-chairs: A. Lopez-Guillermo, Barcelona (Spain) and S. Montoto, London (UK)

10:15 136 INTERFERON-FREE ANTIVIRAL TREATMENT IN B-CELL LYMPHOPROLIFERATIVE

DISORDERS ASSOCIATED WITH CHRONIC HEPATITIS-C VIRUS INFECTION M. Frigeni, Pavia (Italy)

10:30 137 IMMUNOCHEMOTHERAPY WITH OBINUTUZUMAB OR RITUXIMAB IN A SUBSET OF PATIENTS IN THE RANDOMISED GALLIUM TRIAL WITH PREVIOUSLY UNTREATED MARGINAL ZONE LYMPHOMA (MZL)

M. Herold, Erfurt (Germany) 10:45 138 LONG-TERM RESULTS OF THE MULTICENTER PHASE II TRIAL WITH

BENDAMUSTINE AND RITUXIMAB AS FIRST LINE TREATMENT FOR PATIENTS WITH MALT LYMPHOMA (MALT-2008-01)

A. Salar, Barcelona (Spain) 11:00 139 PHASE IIIB STUDY OF LENALIDOMIDE PLUS RITUXIMAB FOLLOWED BY

MAINTENANCE IN RELAPSED OR REFRACTORY NHL: ANALYSIS OF MARGINAL ZONE LYMPHOMA

M. Coleman, New York, NY (USA) 11:15 – 11:40 Room A and B

14-ICML HIGHLIGHTS · “TAKE HOME MESSAGES” J.W. Friedberg, Rochester, NY (USA)

11:40 – 11:50 CLOSURE AND FAREWELL

F. Cavalli, Bellinzona (Switzerland) 13:30 – 18:15 Room B

WORKSHOP - NEW DEVELOPMENTS IN CANINE LYMPHOMA Co-chairs: S. Comazzi, Milan (Italy), F. Guscetti, Zurich (Switzerland) and L. Marconato, Bologna (Italy)

Organized by the European Canine Lymphoma Network open to all 14-ICML attendees

· This icon denotes presentations that will be available online, only for 14-ICML attendees, between July and September 2017, thanks to an unrestricted grant provided by Bristol-Myers Squibb.

- Updated on June 05, 2017 -